BK, what is your take on that quote, as you have been pretty adamant that the pre-clinical work should be highly predictive of our current trial's outcomes. Hoping you may be able to shed some additional insights.
The points you make are absolutely why Leo has termed this Cellceutix's "riskiest drug trial". I am stuck on Mobil so these figures (in the patent) don't show up for me, but it sort of points to other MOA's that might be behind possible effectiveness. Perhaps it shouldn't, but the relative effectiveness to Methotrexate in the exact mouse model gives me a bit more confidence. The little ball is in motion and it will either be red or black. I have my chips on black!
"Figure 1 shows production of IL-20 in mice by Prurisol (at doses of 10 mg/kg or 2 x 10 mg/kg ) and MTX (methotrexate) (at dose 7.5 mg/kg).
Figure 2 shows supression of psoriasis susceptibility related RNA gene induced by stress (PRINS) after administering Prurisol (at doses of 10 mg/kg or 2 x 10 mg/kg) and MTX (7.5 m/kg).
Figure 3 shows appearance of skin after administration of Prurisol and MTX.
Figure 4 shows Normalization of skin in histological parameters compare to fully psoriatic skin and MTX.
Figure 5 shows induction of 12-R lipoxygenase activity by Prurisol and MTX.
Figure 6 shows appearance of skin by naked eye in psoriatic animals and those treated with Prurisol.
Market Data 
Markets 
AI
